Search Result

Pathways Recommended:	GPCR/G Protein

Results for "

Gly 6

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (2) AMPK (1) Apoptosis (5) Autophagy (5) Bacterial (2) Bcl-2 Family (1) c-Met/HGFR (1) Caspase (1) CD47 (1) DGK (1) Drug Intermediate (1) Endogenous Metabolite (3) IGF-1R (1) Interleukin Related (1) JAK (1) Keap1-Nrf2 (1) Mitochondrial Metabolism (4) Mitophagy (2) mTOR (2) NADPH Oxidase (3) NF-κB (1) NO Synthase (1) Oxidative Phosphorylation (1) Parasite (1) PDI (2) PEPCK (1) Phosphatase (2) PI3K (1) Reactive Oxygen Species (ROS) (2) Reference Standards (2) Small Interfering RNA (siRNA) (16) Src (1) STAT (1)
By Research Areas:	Cancer (16) Cardiovascular Disease (2) Endocrinology (1) Infection (3) Inflammation/Immunology (11) Metabolic Disease (9)
Oligonucleotides:	Rat Pre-designed siRNA Sets (4) Mouse Pre-designed siRNA Sets (3) Human Pre-designed siRNA Sets (9) siRNAs (16)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W107464

G6PDi-1 3 Publications Verification	PDI	Metabolic Disease Inflammation/Immunology
G6PDi-1 is a reversible and non-competitive glucose-6-phosphate dehydrogenase (G6PD) inhibitor with an IC₅₀ of 0.07 μM for human G6PD. G6PDi-1 depletes NADPH most strongly in lymphocytes. G6PDi-1 markedly decreases inflammatory cytokine production in T cells .

HY-W590989

GPhos Pd G6 GPhos Pd G6 TES	Drug Intermediate	Others
GPhos Pd G6 (GPhos Pd G6 TES) is a drug intermediate for synthesis of various active compounds.

HY-123962

G6PD activator AG1 5+ Cited Publications	NADPH Oxidase	Metabolic Disease
G6PD activator AG1 is a potent and selective glucose-6-phosphate dehydrogenase (G6PD) agonist with an EC50 of 3 μM. G6PD is an oxidoreductase that catalyzes the oxidation of glucose-6-phosphate to 6-phosphogluconolactone and the simultaneous reduction of NAD phosphate (NADP) to reduced NADP (NADPH). G6PD activator AG1 can reduce hemolysis of human erythrocytes .

HY-P0148

*Gly6* HexaGlycine	Bacterial	Others
Gly6 (Hexaglycine) is a linear glycine oligopeptide with six glycines .

HY-RS05195

G6PR Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
G6PR Human Pre-designed siRNA Set A contains three designed siRNAs for G6PR gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

G6PR Human Pre-designed siRNA Set A G6PR Human Pre-designed siRNA Set A

HY-RS22997

G6pd Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
G6pd Rat Pre-designed siRNA Set A contains three designed siRNAs for G6pd gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

G6pd Rat Pre-designed siRNA Set A G6pd Rat Pre-designed siRNA Set A

HY-RS05194

G6PD Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
G6PD Human Pre-designed siRNA Set A contains three designed siRNAs for G6PD gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

G6PD Human Pre-designed siRNA Set A G6PD Human Pre-designed siRNA Set A

HY-RS05192

G6PC2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
G6PC2 Human Pre-designed siRNA Set A contains three designed siRNAs for G6PC2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

G6PC2 Human Pre-designed siRNA Set A G6PC2 Human Pre-designed siRNA Set A

HY-RS27449

G6pc3 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
G6pc3 Rat Pre-designed siRNA Set A contains three designed siRNAs for G6pc3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

G6pc3 Rat Pre-designed siRNA Set A G6pc3 Rat Pre-designed siRNA Set A

HY-RS20932

G6pc3 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
G6pc3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for G6pc3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

G6pc3 Mouse Pre-designed siRNA Set A G6pc3 Mouse Pre-designed siRNA Set A

HY-RS10633

PLA2G6 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
PLA2G6 Human Pre-designed siRNA Set A contains three designed siRNAs for PLA2G6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PLA2G6 Human Pre-designed siRNA Set A PLA2G6 Human Pre-designed siRNA Set A

HY-RS05193

G6PC3 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
G6PC3 Human Pre-designed siRNA Set A contains three designed siRNAs for G6PC3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

G6PC3 Human Pre-designed siRNA Set A G6PC3 Human Pre-designed siRNA Set A

HY-RS05191

G6PC1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
G6PC1 Human Pre-designed siRNA Set A contains three designed siRNAs for G6PC1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

G6PC1 Human Pre-designed siRNA Set A G6PC1 Human Pre-designed siRNA Set A

HY-RS21881

Ly6g6f Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Ly6g6f Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ly6g6f gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Ly6g6f Mouse Pre-designed siRNA Set A Ly6g6f Mouse Pre-designed siRNA Set A

HY-RS26283

Ly6g6d Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Ly6g6d Rat Pre-designed siRNA Set A contains three designed siRNAs for Ly6g6d gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Ly6g6d Rat Pre-designed siRNA Set A Ly6g6d Rat Pre-designed siRNA Set A

HY-RS07900

LY6G6F Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
LY6G6F Human Pre-designed siRNA Set A contains three designed siRNAs for LY6G6F gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LY6G6F Human Pre-designed siRNA Set A LY6G6F Human Pre-designed siRNA Set A

HY-RS07898

LY6G6C Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
LY6G6C Human Pre-designed siRNA Set A contains three designed siRNAs for LY6G6C gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LY6G6C Human Pre-designed siRNA Set A LY6G6C Human Pre-designed siRNA Set A

HY-RS07899

LY6G6D Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
LY6G6D Human Pre-designed siRNA Set A contains three designed siRNAs for LY6G6D gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LY6G6D Human Pre-designed siRNA Set A LY6G6D Human Pre-designed siRNA Set A

HY-RS28398

Ly6g6f Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Ly6g6f Rat Pre-designed siRNA Set A contains three designed siRNAs for Ly6g6f gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Ly6g6f Rat Pre-designed siRNA Set A Ly6g6f Rat Pre-designed siRNA Set A

HY-RS19787

Ly6g6d Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Ly6g6d Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ly6g6d gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Ly6g6d Mouse Pre-designed siRNA Set A Ly6g6d Mouse Pre-designed siRNA Set A

HY-18293

NSC 33994	JAK Autophagy	Cancer
NSC 33994 (G6) is a selective JAK2 inhibitor, with an IC₅₀ of 60 nM .

HY-16443

S-4048	Phosphatase	Metabolic Disease
S-4048 is a Glucose-6-phosphatase (G6Pase) inhibitor with an IC₅₀ value of 9.4 nM for rat microsomes.

HY-123046

AS1708727 3 Publications Verification	Autophagy	Metabolic Disease Cancer
AS1708727 is an orally active Foxo1 inhibitor, with EC₅₀ values of 0.33 μM and 0.59 μM for G6Pase and PEPCK, respectively .

HY-111896

7-Methoxyrosmanol 7-O-Methoxyrosmanol	PEPCK	Others
7-Methoxyrosmanol (7-O-Methoxyrosmanol), a phenolic diterpene isolated from rosemary, suppresses the cAMP responsiveness of PEPCK and G6Pase promoters .

HY-106328

Fluasterone	Mitochondrial Metabolism	Metabolic Disease Inflammation/Immunology Cancer
Fluasterone is a potent *G6PD* inhibitor with a K_i of 0.51 μM. Fluasterone has anti-inflammatory, cancer preventive, and anti-diabetic effects. Fluasterone is orally active .

HY-115449

Chromeceptin 1 Publications Verification 94G6	IGF-1R Akt mTOR	Cancer
Chromeceptin (94G6) is an IGF signaling pathway inhibitor. Chromeceptin suppresses IGF2 expression at mRNA and protein levels in hepatocyte and HCC cells. Chromeceptin inhibits the phosphorylation levels of AKT and mTOR .

HY-117746

KSK120	Bacterial	Infection
KSK120 is a potent inhibitor of drug-resistant infections with specific activity against Chlamydia trachomatis (C. trachomatis). KSK120 inhibits the developmental cycle of C. trachomatis, thereby reducing the infectivity of progeny bacteria. KSK120 targets the glucose-6-phosphate (G-6P) metabolic pathway of C. trachomatis, showing its potential application in antimicrobial inhibition. The mechanism of KSK120 may involve inhibition of the transcriptional machinery, which provides new ideas for the development of specific drugs against C. trachomatis infection .

HY-N0120A

Polydatin 10+ Cited Publications Piceid	Autophagy Apoptosis Mitophagy	Inflammation/Immunology Cancer
Polydatin (Piceid), extracted from the roots of Reynoutria japonica, a widely used traditional Chinese remedies, possesses anti-inflammatory activity in several experimental models. Polydatin (Piceid) inhibits G6PD and induces oxidative and ER stresses.

HY-W587796

6-Phosphoglucono-δ-lactone 6-PGδL; 6-Phosphonoglucono-D-lactone	Endogenous Metabolite PDI	Cardiovascular Disease Metabolic Disease Cancer
6-Phosphoglucono-δ-lactone (6-PGδL) is a reversal substrate of glucose-6-phosphate dehydrogenase (G6PD). 6-Phosphoglucono-δ-lactone is an intermediate compound in the oxidative branch of the pentose phosphate pathway (PPP). 6-Phosphoglucono-δ-lactone produced from D-glucose-6-phosphate by glucose-6-phosphate dehydrogenase (G6PDH) and is converted to 6-phosphoglutonate by lactonase. 6-Phosphoglucono-δ-lactone can be used for heart failure, type 2 diabetes and cancers research .

HY-106328R

Fluasterone (Standard)	Mitochondrial Metabolism Reference Standards	Metabolic Disease Inflammation/Immunology Cancer
Fluasterone (Standard) is the analytical standard of Fluasterone. This product is intended for research and analytical applications. Fluasterone is a potent G6PD inhibitor with a Ki of 0.51 μM. Fluasterone has anti-inflammatory, cancer preventive, and anti-diabetic effects. Fluasterone is orally active .

HY-138877A

Phosphoglycolic acid lithium	Phosphatase	Cancer
Phosphoglycolic acid (lithium) is a competitive inhibitor of phosphoglycerate mutase (PGAM)-B, an enzyme of the glycolytic pathway. Phosphoglycolic acid increases basal and fMLF-induced levels of G6P in intact neutrophils. Phosphoglycolic acid thereby increases upstream intermediates in neutrophils, thereby amplifying the respiratory oxidative burst .

HY-N0120AR

Polydatin (Standard) 10+ Cited Publications Piceid (Standard)	Reference Standards Autophagy Apoptosis Mitophagy	Inflammation/Immunology Cancer
Polydatin (Standard) is the analytical standard of Polydatin. This product is intended for research and analytical applications. Polydatin (Piceid), extracted from the roots of Reynoutria japonica, a widely used traditional Chinese remedies, possesses anti-inflammatory activity in several experimental models. Polydatin (Piceid) inhibits G6PD and induces oxidative and ER stresses.

HY-W010342

6-Aminonicotinamide 5+ Cited Publications	NADPH Oxidase	Cancer
6-Aminonicotinamide, a potent antimetabolite of nicotinamide, is competitive NADP ⁺-dependent enzyme glucose-6-phosphate dehydrogenase (G6PD) inhibitor (K_i=0.46 μM). 6-Aminonicotinamide resultis ATP depletion and synergizes with DNA-crosslinking chemotherapy agents, such as Cisplatin (HY-17394), in killing cancer cells .

HY-W010342R

6-Aminonicotinamide (Standard)	NADPH Oxidase	Cancer
6-Aminonicotinamide, a potent antimetabolite of nicotinamide, is competitive NADP+-dependent enzyme glucose-6-phosphate dehydrogenase (G6PD) inhibitor (Ki=0.46 μM). 6-Aminonicotinamide resultis ATP depletion and synergizes with DNA-crosslinking chemotherapy agents, such as Cisplatin (HY-17394), in killing cancer cells .

HY-16438

RRx-001 Maximum Cited Publications 19 Publications Verification Nibrozetone	CD47 Apoptosis Parasite	Infection Inflammation/Immunology Cancer
RRx-001, a hypoxia-selective epigenetic agent and studied as a radio- and chem-sensitizer, triggers apoptosis and overcomes agent resistance in myeloma. RRx-001 exhibits potent anti-tumor activity with minimal toxicity . RRx-001 is a dual small molecule checkpoint inhibitor by downregulating CD47 and SIRP-α . RRx-001 is a potent inhibitor of *G6PD* and shows potent antimalarial activity .

HY-125863

Glucose-6-phosphate dehydrogenase, Microorganism G6PD	Endogenous Metabolite	Metabolic Disease Cancer
Glucose-6-phosphate dehydrogenase, Microorganism (G6PD) is the rate-limiting enzyme of the pentose phosphate pathway. Glucose-6-phosphate dehydrogenase, Microorganism is a primary source of NADPH in antioxidant pathways, nitric oxide synthase, NADPH oxidase, cytochrome p450 systems, and others. Glucose-6-phosphate dehydrogenase, Microorganism is applicable in research related to diabetes, endothelial dysfunction, cancer, and cardiomyopathy .

HY-18705

Azoramide 5 Publications Verification	Apoptosis Reactive Oxygen Species (ROS) Caspase Bcl-2 Family Mitochondrial Metabolism	Endocrinology
Azoramide is a potent, orally active small-molecule modulator of the unfolded protein response (UPR). Azoramide improves ER protein folding and elevates ER chaperone capacity, which together protects cells against ER stress. Azoramide alleviates PLA2G6 mutant-induced ER stress through modulating unfolded protein response, and enhances the CERB signaling to rescue mitochondrial function, thereby preventing apoptosis of DA neurons. Azoramide has antidiabetic activity .

HY-122949

Momordicine I	Apoptosis Autophagy DGK Mitochondrial Metabolism NO Synthase PI3K Akt Interleukin Related Src AMPK mTOR NF-κB c-Met/HGFR STAT Keap1-Nrf2 Reactive Oxygen Species (ROS) Oxidative Phosphorylation Endogenous Metabolite	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
Momordicine I is a cucurbitane-type triterpenoids. Momordicine I suppresses glioma growth by promoting apoptosis and impairing mitochondrial oxidative phosphorylation. Momordicine I inhibits glycolysis, lipid metabolism, induces autophagy in HNC cells to suppress head and neck cancer growth. Momordicine I alleviates isoproterenol-induced cardiomyocyte hypertrophy through suppression of *PLA2G6* and DGK-ζ. Momordicine I exerts its cardiovascular benefits by upregulating nitric oxide, inhibiting the activity of angiotensin-converting enzyme (ACE), activating the PI3K/Akt pathway, reducing oxidative stress and inflammation. Momordicine I inhibits AKT1, IL-6, and SRC, suggesting its potential application in type 2 diabetes .

Cat. No.	Product Name	Target	Research Area

HY-P0148

*Gly6* HexaGlycine	Bacterial	Others
Gly6 (Hexaglycine) is a linear glycine oligopeptide with six glycines .

HY-P0148A

Gly6 hydrochloride HexaGlycine hydrochloride	Peptides	Others
Gly6 hydrochloride (Hexaglycine hydrochloride) is a linear glycine oligopeptide with six glycines .

HY-P10109

G6PI 325-339 (human)	Peptides	Inflammation/Immunology
G6PI 325-339 (human) is an efficient inducer of arthritis in B10.Q mice. G6PI 325-339 (human) primes Th1 and Th17 cells cross-reacted with the murine G6PI protein. G6PI 325-339 (human) induces arthritis model operating through a T and B cell-dependent pathway but without antibody effector mechanisms .

HY-P10109A

G6PI 325-339 (human) hydrochloride hG6PI (325-339) hydrochloride	Peptides	Inflammation/Immunology
G6PI 325-339 (human) hydrochloride is an efficient inducer of arthritis in B10.Q mice. G6PI 325-339 (human) hydrochloride primes Th1 and Th17 cells cross-reacted with the murine G6PI protein. G6PI 325-339 (human) hydrochloride induces arthritis model operating through a T and B cell-dependent pathway but without antibody effector mechanisms .

Cat. No.	Product Name	Target	Research Area

HY-P990199

Anti-Mouse Ly6G/Ly6C Antibody (NIMP-R14)	Inhibitory Antibodies	Infection Inflammation/Immunology Cancer
Anti-Mouse Ly6G/Ly6C Antibody (NIMP-R14) is an anti-mouse *Ly6G/Ly6C* IgG2b monoclonal antibody. Anti-Mouse Ly6G/Ly6C Antibody (NIMP-R14) can deplete granulocytes and monocytes. Anti-Mouse Ly6G/Ly6C Antibody (NIMP-R14) can be used for researches on infection conditions and cancer such as pancreatic cancer and Orientia tsutsugamushi infection .

HY-P99142

Anti-Mouse Ly-6G/Ly-6C Antibody (RB6-8C5) 1 Publications Verification	Inhibitory Antibodies	Inflammation/Immunology
Anti-Mouse Ly-6G/Ly-6C Antibody (RB6-8C5) is an anti-mouse *Ly-6G/Ly-6C* IgG2b monoclonal antibody. Anti-Mouse Ly-6G/Ly-6C Antibody (RB6-8C5) can deplete neutrophils and monocytes. Anti-Mouse Ly-6G/Ly-6C Antibody (RB6-8C5) can be used for research on immunology .

HY-P991184

Anti-LY6G6D Antibody (1G4)	Inhibitory Antibodies	Cancer
Anti-LY6G6D Antibody (1G4) is a humanized IgG1 monoclonal antibody that targets *LY6G6D*. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks